title: Prolonged remission of platinum-refractory ovarian cancer with docetaxel: brief report and review of literature.
abstract: Platinum-based chemotherapy is the standard treatment for ovarian cancer, with response rates of 70-80%. Docetaxel has an increasing role as salvage therapy in patients with platinum-refractory ovarian cancer. In this report, we present the case of a patient with platinum-refractory ovarian cancer who achieved a long-term complete remission with docetaxel therapy. Two years after completion of chemotherapy with docetaxel, she continues to have no evidence of disease.
authors.affiliation: University of Texas, M.D. Anderson Cancer Center, Houston, USA.
authors.forename: O
authors.initials: O
authors.lastname: Balat
authors.forename: A P
authors.initials: AP
authors.lastname: Kudelka
authors.forename: C L
authors.initials: CL
authors.lastname: Edwards
authors.forename: C F
authors.initials: CF
authors.lastname: Verschraegen
authors.forename: J J
authors.initials: JJ
authors.lastname: Kavanagh
mesh_terms: D000972:Antineoplastic Agents, Phytogenic / Q000627:therapeutic use*; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use; D002945:Cisplatin / Q000008:administration & dosage; D000077143:Docetaxel; D019008:Drug Resistance, Neoplasm; D005260:Female; D006801:Humans; D008875:Middle Aged; D010051:Ovarian Neoplasms / Q000188:drug therapy*; D017239:Paclitaxel / Q000031:analogs & derivatives* / Q000627:therapeutic use; D012074:Remission Induction; D016879:Salvage Therapy; D043823:Taxoids
chemical_list: D000972:Antineoplastic Agents, Phytogenic; D043823:Taxoids; D000077143:Docetaxel; D017239:Paclitaxel; D002945:Cisplatin